Cargando…

Current Pharmacological Strategies for Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a lethal, X-linked neuromuscular disorder caused by the absence of dystrophin protein, which is essential for muscle fiber integrity. Loss of dystrophin protein leads to recurrent myofiber damage, chronic inflammation, progressive fibrosis, and dysfunction of mus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Shanshan, Chen, Zihao, Yu, Yuanyuan, Zhang, Ning, Jiang, Hewen, Zhang, Ge, Zhang, Zongkang, Zhang, Baoting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417245/ https://www.ncbi.nlm.nih.gov/pubmed/34490244 http://dx.doi.org/10.3389/fcell.2021.689533

Ejemplares similares

Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy
por: Ogura, Yuji, et al.
Publicado: (2014)

Long-term culture of patient-derived cardiac organoids recapitulated Duchenne muscular dystrophy cardiomyopathy and disease progression
por: Marini, Vittoria, et al.
Publicado: (2022)

Gpr18 agonist dampens inflammation, enhances myogenesis, and restores muscle function in models of Duchenne muscular dystrophy
por: Dort, Junio, et al.
Publicado: (2023)

Editorial: Muscular dystrophies: Current therapeutic advances to improve and restore muscle homeostasis
por: Bargiela, Ariadna, et al.
Publicado: (2022)

Beneficial impacts of neuromuscular electrical stimulation on muscle structure and function in the zebrafish model of Duchenne muscular dystrophy
por: Kilroy, Elisabeth A, et al.
Publicado: (2022)

Editorial: Aptamer-based structural biology, computational modelling, translational research and drug discovery, Volume II
por: Ma, Yuan, et al.
Publicado: (2023)

Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy
por: Mendell, Jerry R., et al.
Publicado: (2023)

Current and emerging treatment strategies for Duchenne muscular dystrophy
por: Mah, Jean K
Publicado: (2016)

Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update
por: Sun, Chengmei, et al.
Publicado: (2020)

Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: The present and the future
por: Zhang, Yihao, et al.
Publicado: (2022)

Characterization of cardiac involvement in children with LMNA-related muscular dystrophy
por: Cesar, Sergi, et al.
Publicado: (2023)

Pharyngeal pathology in a mouse model of oculopharyngeal muscular dystrophy is associated with impaired basal autophagy in myoblasts
por: Zhang, Yu, et al.
Publicado: (2022)

Current care practices for patients with Duchenne muscular dystrophy in China
por: Zhang, Shu, et al.
Publicado: (2022)

Biomarkers of Duchenne muscular dystrophy: current findings
por: Szigyarto, Cristina Al-Khalili, et al.
Publicado: (2018)

Targeting the Ubiquitin-Proteasome System in Limb-Girdle Muscular Dystrophy With CAPN3 Mutations
por: Lasa-Elgarresta, Jaione, et al.
Publicado: (2022)

Effects of mutant lamins on nucleo-cytoskeletal coupling in Drosophila models of LMNA muscular dystrophy
por: Shaw, Nicholas M., et al.
Publicado: (2022)

Connective Tissue Growth Factor: From Molecular Understandings to Drug Discovery
por: Chen, Zihao, et al.
Publicado: (2020)

Duchenne and Becker muscular dystrophy in adolescents: current perspectives
por: Andrews, Jennifer G, et al.
Publicado: (2018)

Modeling Patient-Specific Muscular Dystrophy Phenotypes and Therapeutic Responses in Reprogrammed Myotubes Engineered on Micromolded Gelatin Hydrogels
por: Barthélémy, Florian, et al.
Publicado: (2022)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Advances in genetic therapeutic strategies for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2015)

Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy
por: Happi Mbakam, Cedric, et al.
Publicado: (2022)

Duchenne muscular dystrophy: disease mechanism and therapeutic strategies
por: Bez Batti Angulski, Addeli, et al.
Publicado: (2023)

Drug development progress in duchenne muscular dystrophy
por: Deng, Jiexin, et al.
Publicado: (2022)

Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2015)

Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding
por: Chen, Zefeng, et al.
Publicado: (2023)

Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy
por: Ogundele, Michael, et al.
Publicado: (2021)

Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through β-Catenin in Facioscapulohumeral Muscular Dystrophy
por: Ganassi, Massimo, et al.
Publicado: (2022)

Genetic Modifiers of Duchenne Muscular Dystrophy in Chinese Patients
por: Chen, Menglong, et al.
Publicado: (2020)

Current Translational Research and Murine Models For Duchenne Muscular Dystrophy
por: Rodrigues, Merryl, et al.
Publicado: (2016)

Current Outline of Exon Skipping Trials in Duchenne Muscular Dystrophy
por: Eser, Gökçe, et al.
Publicado: (2022)

Biomarkers in Duchenne Muscular Dystrophy: Current Status and Future Directions
por: Fortunato, Fernanda, et al.
Publicado: (2023)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

The role of fibrosis in Duchenne muscular dystrophy
por: KLINGLER, WERNER, et al.
Publicado: (2012)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Targeting angiogenesis in Duchenne muscular dystrophy
por: Podkalicka, Paulina, et al.
Publicado: (2019)

Regenerative biomarkers for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9il7g51kt5umtpsr3ergrcgp3h